同步经动脉化疗栓塞术与射频消融术治疗大肝癌
Simultaneous transarterial chemoembolization and radiofrequency ablation for large hepatocellular carcinoma.
作者信息
Duan Feng, Bai Yan-Hua, Cui Li, Li Xiao-Hui, Yan Jie-Yu, Wang Mao-Qiang
机构信息
Department of Interventional Radiology, General Hospital of Chinese People's Liberation Army, Beijing 100853, China.
出版信息
World J Gastrointest Oncol. 2020 Jan 15;12(1):92-100. doi: 10.4251/wjgo.v12.i1.92.
BACKGROUND
Hepatocellular carcinoma (HCC) is a common cancer and a leading cause of tumor-related death. Patients with large HCC (≥ 8 cm) are at an advanced stage and have poor prognosis, and hepatic resection may not be suitable, and the incidence of postoperative recurrence is high.
AIM
To evaluate recurrence and mid-term survival of patients with large HCC treated by transcatheter arterial chemoembolization (TACE) and radiofrequency ablation (RFA).
METHODS
This was a retrospective study. From 2010 to 2013, 46 consecutive patients with large HCC were treated with simultaneous TACE and RFA. Thirty-five of 46 patients had a single tumor. Progression-free survival (PFS) and overall survival (OS) were analyzed at 2 years and 3 years, respectively.
RESULTS
Forty-six patients treated by simultaneous TACE and RFA had no significant complications and treatment was successful. After 3 years, median PFS and OS were 10.21 ± 1.58 mo and 26.44 ± 2.26 mo, retrospectively. The survival rate was 67.5% after 2 years and 55.67% after 3 years.
CONCLUSION
These preliminary data show that simultaneous TACE and RFA are safe and effective for large HCC.
背景
肝细胞癌（HCC）是一种常见癌症，也是肿瘤相关死亡的主要原因。大肝癌（≥8 cm）患者处于晚期，预后较差，肝切除术可能并不适用，且术后复发率较高。
目的
评估经动脉化疗栓塞术（TACE）联合射频消融术（RFA）治疗大肝癌患者的复发情况及中期生存率。
方法
这是一项回顾性研究。2010年至2013年，连续46例大肝癌患者接受了TACE与RFA同步治疗。46例患者中有35例为单发肿瘤。分别在2年和3年时分析无进展生存期（PFS）和总生存期（OS）。
结果
46例接受TACE与RFA同步治疗的患者无明显并发症，治疗成功。回顾性分析显示，3年后，中位PFS和OS分别为10.21±1.58个月和26.44±2.26个月。2年生存率为67.5%，3年生存率为55.67%。
结论
这些初步数据表明，TACE与RFA同步治疗大肝癌安全有效。
Zotero 插件